The two study groups were comparable in age, female-to-male ratio, proportions of hypertension, diabetes, ever-smokers, nAMD subtypes, history of receiving PDT, follow-up period, and number of anti-VEGF therapies before switching. The gene discussed is VEGFA; the disease is diabetes mellitus.